SCHEMBL6465520

SCHEMBL6465520

COc1cc2nc(Nc3nc(OC(=O)C(F)(F)F)c4cc(OCCCl)ccc4n3)nc(C)c2cc1OC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.38
MAPT P10636 8/20 0.38
KMT2A Q03164 6/20 0.38
KDM4E B2RXH2 6/20 0.38
ALDH1A1 P00352 5/20 0.38
MEN1 O00255 5/20 0.38
TDP1 Q9NUW8 2/20 0.38
PSMD14 O00487 1/20 0.38
APAF1 O14727 1/20 0.38
MITF O75030 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
PTK2B Q14289 1/20 0.38
TDP2 O95551 1/20 0.37
USP2 O75604 2/20 0.37
LMNA P02545 2/20 0.37
RAB9A P51151 1/20 0.37
AURKA O14965 1/20 0.37
TP53 P04637 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6470212 0.97 TDP2 (0.37) NPSR1MAPTKMT2AKDM4EALDH1A1
SCHEMBL6466266 0.92 RAF1 (0.39) NPSR1MAPTKMT2AKDM4EALDH1A1
SCHEMBL6467467 0.92 TDP2 (0.38) NPSR1MAPTKMT2AKDM4EALDH1A1
SCHEMBL6469716 0.90 ALDH1A1 (0.37) NPSR1MAPTKMT2AKDM4EALDH1A1
SCHEMBL6470081 0.90 NPSR1 (0.37) NPSR1MAPTKMT2AKDM4EALDH1A1
SCHEMBL6467999 0.90 FGFR2 (0.40) NPSR1MAPTKMT2AKDM4EALDH1A1
SCHEMBL6467888 0.90 TDP2 (0.36) NPSR1MAPTKMT2AKDM4EALDH1A1
SCHEMBL6467974 0.89 KDR (0.38) MAPTKMT2AKDM4EALDH1A1MEN1
SCHEMBL6469208 0.88 TDP2 (0.35) NPSR1MAPTKMT2AKDM4EALDH1A1
SCHEMBL6467450 0.88 FGFR2 (0.40) NPSR1MAPTKMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US claimed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO claimed
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US disclosed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections POLI, POLK, POLB NPSR1 4093/4885MAPT 3552/4885KMT2A 2156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.